Compass Pathways (NASDAQ:CMPS) Shares Up 5.9% - Time to Buy?

Key Points

• Compass Pathways shares rose 5.9% to about $14.12, with trading volume roughly 60% below its average. The stock’s 50-day and 200-day moving averages were $12.85 and $9.82, respectively.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $23.36, although some firms maintain sell ratings. B. Riley raised its target to $22 and assigned a buy rating.
• The company reported a quarterly loss of $1.88 per share, missing the $0.39 consensus estimate by $1.49. Compass is a clinical-stage biotechnology company developing psilocybin-based therapy for treatment-resistant depression, making its outlook dependent on clinical and regulatory progress.

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report)'s share price traded up 5.9% on Monday . The stock traded as high as $14.00 and last traded at $14.1150. Approximately 1,467,043 shares changed hands during trading, a decline of 60% from the average daily volume of 3,650,261 shares. The stock had previously closed at $13.33.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on CMPS shares. Wall Street Zen cut Compass Pathways from a "sell" rating to a "strong sell" rating in a report on Monday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Compass Pathways in a research note on Friday, July 17th. B. Riley Financial boosted their price objective on Compass Pathways from $17.00 to $22.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Oppenheimer reissued an "outperform" rating on shares of Compass Pathways in a report on Wednesday, August 5th. Finally, Compass Point set a $25.00 price target on shares of Compass Pathways in a report on Tuesday, July 7th. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, Compass Pathways presently has a consensus rating of "Moderate Buy" and a consensus price target of $23.36.

Compass Pathways Stock Performance

The business's fifty day simple moving average is $12.85 and its 200-day simple moving average is $9.82. The firm has a market capitalization of $1.96 billion, a PE ratio of -3.07 and a beta of 2.50. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.30 and a current ratio of 1.30.

Compass Pathways (NASDAQ:CMPS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($1.49). As a group, equities research analysts expect that Compass Pathways PLC Sponsored ADR will post -1.26 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of CMPS. Ancora Advisors LLC purchased a new stake in Compass Pathways in the second quarter worth about $43,000. EverSource Wealth Advisors LLC increased its position in Compass Pathways by 67.7% during the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company's stock valued at $26,000 after buying an additional 1,920 shares in the last quarter. Persistent Asset Partners Ltd purchased a new position in Compass Pathways during the fourth quarter valued at $38,000. Caitong International Asset Management Co. Ltd purchased a new position in Compass Pathways during the fourth quarter valued at $47,000. Finally, Advisory Services Network LLC bought a new stake in Compass Pathways in the third quarter worth $41,000. 46.19% of the stock is owned by hedge funds and other institutional investors.

Compass Pathways Company Profile

Compass Pathways NASDAQ: CMPS is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source